This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Senju Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Mochida Pharmaceutical., Ltd.. Active years: 2025-2026.
Company Filing History:
2 out of 229 
1 out of 229 
1 out of 5 Years Active: 2025-2026
Title: Innovations by Takeshi Tarui in Pharmaceutical Development
Introduction
Takeshi Tarui is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of dry eye. With a total of 2 patents to his name, his work showcases the intersection of innovation and healthcare.
Latest Patents
Takeshi Tarui's latest patents focus on pharmaceutical drugs containing heterocyclidene acetamide derivatives. One of his key disclosures provides a means for treating dry eye. This composition includes (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalene-1-yl)acetamide, along with a pharmaceutically acceptable salt or solvate thereof. The composition also features a Vi/Vc zone inhibitor, which enhances its effectiveness in treating dry eye.
Career Highlights
Throughout his career, Takeshi Tarui has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Senju Pharmaceutical Co., Ltd. and Mochida Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Takeshi has collaborated with various professionals in the field, including his coworker Shinya Kobayashi. These collaborations have fostered an environment of innovation and have led to advancements in pharmaceutical research.
Conclusion
Takeshi Tarui's contributions to the pharmaceutical industry, particularly in the treatment of dry eye, highlight his role as an innovative inventor. His patents reflect a commitment to improving healthcare through scientific advancements.